文献速递泌尿男性生殖肿瘤支持与姑息治疗

高危膀胱癌卡介苗联合免疫检查点抑制剂试验中的删失模式与不一致结果

Censoring patterns and inconsistent results in checkpoint inhibitor and adjuvant BCG trials for high-risk bladder cancer.
PubMed 文献 · Eur J Cancer · 2026-04-12

三项随机对照试验(CREST、POTOMAC、ALBAN)分别评估沙沙利单抗、度伐利尤单抗和阿替利珠单抗联合膀胱内卡介苗(BCG)治疗高危非肌层浸润性膀胱癌(HR-NMIBC)。CREST和POTOMAC显示无事件/无病生存期(EFS/DFS)改善,而ALBAN为阴性。作者提出,毒性相关停药可能导致 informative censoring(信息性删失),从而人为富集健康患者并偏倚EFS/DFS,基于重建Kaplan-Meier曲线的敏感性分析显示仅修改少数患者即可侵蚀POTOMAC和CREST报告的获益。

要点

  • CREST和POTOMAC显示EFS/DFS改善,ALBAN阴性,结果不一致。
  • 实验组毒性相关停药可能导致信息性删失,人为富集健康患者。
  • 基于重建Kaplan-Meier曲线的敏感性分析中,仅修改少数患者即可侵蚀POTOMAC和CREST的EFS/DFS获益。

核心结论

  • 信息性删失可能是免疫检查点抑制剂联合BCG试验中疗效结果不一致的重要且未被充分认识的原因。

研究设计与样本

  • 本文为针对三项随机对照试验(CREST、POTOMAC、ALBAN)的探索性分析,基于重建的Kaplan-Meier曲线进行敏感性分析。

主要发现

  • CREST和POTOMAC显示EFS/DFS改善,ALBAN为阴性。
  • 在POTOMAC和CREST中,仅修改少数患者即可侵蚀所报告的EFS/DFS获益。
  • 免疫治疗联合BCG显著增加毒性,支持毒性相关信息性删失可能对三项试验产生差异性影响。

临床怎么用

  • 在解读开放标签、毒性差异明显的免疫治疗试验的时间-事件终点时,应系统关注删失机制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Intravesical Bacillus Calmette-Guérin (BCG) is the standard-of-care treatment for high-risk non-muscle invasive bladder cancer (HR-NMIBC). However, patients with BCG-unresponsive disease are unlikely to benefit from further BCG. To overcome BCG unresponsiveness, the addition of immune checkpoint inhibition (ICI) to BCG has been investigated in three recently randomized controlled trials: CREST, POTOMAC, and ALBAN, studying sasanlimab, durvalumab, and atezolizumab, respectively. While CREST and POTOMAC demonstrated improvements in event/disease-free survival (EFS/DFS), ALBAN was negative. Several potential explanations have been proposed for these discrepant findings. We propose an additional explanation: censoring. In the experimental arm, toxicity-related discontinuation may preferentially remove frailer patients, artificially enriching the remaining population for healthier individuals potentially biasing EFS or DFS. We explored censoring patterns across trials and conducted sensitivity analyses based on reconstructed Kaplan-Meier curves, and modifying only a few patients in POTOMAC and CREST eroded the EFS/DFS benefit as reported. The addition of immunotherapy to BCG significantly increases toxicity, and supports that some level of toxicity-related informative censoring might have differentially affected the three trials. Informative censoring may represent an important, underrecognized explanation for the inconsistent efficacy results reported across ICI plus BCG trials. More broadly, given the expanding use of immunotherapy in earlier disease settings and the reliance on time-to-event endpoints in open-label trials with differential toxicity, systematic attention to censoring mechanisms is essential for accurate interpretation.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Develtere D, Tsantoulis P, Olivier T, et al. Censoring patterns and inconsistent results in checkpoint inhibitor and adjuvant BCG trials for high-risk bladder cancer. Eur J Cancer. 2026. PMID: 42019224. doi:10.1016/j.ejca.2026.116740

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。